How Is Soliris® Dosed and Administered?

Your initial Soliris treatment (induction phase) involves a 600-mg infusion once a week for the first 4 weeks. Starting at Week 5, you will receive a 900-mg infusion every 2 weeks (maintenance phase). It is very important to make sure that you do not miss any scheduled treatments in order to continue to control hemolysis and to experience the full benefits of Soliris therapy.1,2

Soliris is administered through an intravenous infusion (introduction of a solution into a vein). The 35-minute infusion must be prepared and administered by a qualified, licensed healthcare professional, usually at a healthcare clinic, doctor’s office, or infusion center.1

For best results:

  • It's important not to miss any treatments. Soliris only controls hemolysis as long as you
    take it1,2
  • Make sure your doctor knows about any other drugs you are taking
  • Speak with your doctor before you take any vitamins, over-the-counter drugs, or natural supplements, as these may affect your therapy as well




IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).

Please see full prescribing information for SOLIRIS, including boxed WARNING regarding serious meningitis.


References: 1. Soliris® [package insert]. Cheshire, CT: Alexion Pharmaceuticals Inc; 2009. 2. Rosse WF, Hillmen P, Schreiber AD. Immune-mediated hemolytic anemia. Hematology (Am Soc Hematol Educ Program). 2004:48-62.